Anti-sclerostin - Is there an indication?

Injury

Volumn 47, Issue , 2016, Pages S31-S35

  Larsson, Sune ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

anabolic; fracture healing; osteoporosis; romosozumab; Sclerostin; sclerostin antibody

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; MONOCLONAL ANTIBODY; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; ROMOSOZUMAB; SCLEROSTIN; SCLEROSTIN ANTIBODY; STRONTIUM RANELATE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ARTICLE; BONE DENSITY; BONE MASS; DRUG EFFICACY; DRUG SAFETY; FRACTURE; FRACTURE HEALING; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; HUMAN; LUMBAR SPINE; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SOTS GENE; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE REMODELING; DISEASE MODEL; DRUG EFFECTS; FEMALE; FRACTURES, BONE; GENETIC MARKER; HAPLORHINI; HYPEROSTOSIS; LUMBAR VERTEBRA; MALE; METABOLISM; MOUSE; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; SYNDACTYLY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DISEASE MODELS, ANIMAL; FEMALE; FRACTURES, BONE; GENETIC MARKERS; HAPLORHINI; HUMANS; HYPEROSTOSIS; LUMBAR VERTEBRAE; MALE; MICE; OSTEOPOROSIS, POSTMENOPAUSAL; SYNDACTYLY;

EID: 84953455697     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/S0020-1383(16)30008-0     Document Type: Article

References (17)

1. AS Truswell Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease J Bone Joint Surg 40-B 1958 209 218
2. Hausen Scleroosteose H Opitz F Schmid Handbuch der Kinderheilkunde 1967 Springer Verlag Berlin 351 355
3. W Balemans, M Ebeling, N Patel, E Van Hul, P Olson, M Dioszegi et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet 10 2001 537 543
4. H Hamersma, J Gardner, P Beighton The natural history of sclerosteosis Clin Genet 63 2003 192 197
5. ME Brunkow, JC Gardner, J Van Ness, BW Paeper, BR Kovacevich, S Proll et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am J Hum Genet 68 2001 577 589
6. C Galli, G Passeri, GM Macaluso Osteocytes and WNT: the mechanical control of bone formation J Dent Res 89 2010 331 343
7. M van Dinther, J Zhang, SE Weidauer, V Boschert, EM Muth, A Knappik et al. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostinmediated antagonism of Wnt/LRP6 signaling PloS one 8 2013 e62295
8. X Li, MS Ominsky, QT Niu, N Sun, B Daugherty, D D'Agostin et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength J Bone Miner Res 23 2008 860 869
9. X Li, MS Ominsky, KS Warmington, S Morony, J Gong, J Cao et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 2009 578 588
10. X Li, KS Warmington, QT Niu, FJ Asuncion, M Barrero, M Grisanti et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats J Bone Miner Res 25 2010 2647 2656
11. MS Ominsky, F Vlasseros, J Jolette, SY Smith, B Stouch, G Doellgast et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength J Bone Miner Res 25 2010 948 959
12. D Padhi, G Jang, B Stouch, L Fang, E Posvar Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 26 2011 19 26
13. MR McClung, A Grauer, S Boonen, MA Bolognese, JP Brown, A Diez-Perez et al. Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 370 2014 412 420
14. FJ Secreto, LH Hoeppner, JJ Westendorf Wnt signaling during fracture repair Curr Osteoporos Rep 7 2009 64 69
15. Y Chen, HC Whetstone, AC Lin, P Nadesan, Q Wei, R Poon et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing PLoS medicine 4 2007 e249
16. JB Kim, P Leucht, K Lam, C Luppen, D Ten Berge, R Nusse et al. Bone regeneration is regulated by wnt signaling J Bone Miner Res 22 2007 1913 1923
17. MS Ominsky, C Li, X Li, HL Tan, E Lee, M Barrero et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones J Bone Miner Res 26 2011 1012 1021